He Fangfei, Zhu Lichong, Zhou Xiaohan, Zhang Peisen, Cheng Junwei, Qiao Yuanyuan, Feng Yicheng, Yue Saisai, Xu Man, Guan Jiaoqiong, Li Xiaoming, Ao Zhuo, Qin Meng, Hou Yi, Han Dong
CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
ACS Appl Mater Interfaces. 2022 Jun 6. doi: 10.1021/acsami.2c03530.
Enhanced angiography based on magnetic resonance imaging (MRI) has emerged as a noninvasive, robust, and high-resolution imaging technique for the clinical evaluation of vascular diseases. However, the effects of clinical Gd-chelating contrast agents are unsatisfactory for MRI contrast enhancement owing to their short blood half-life caused by rapid vascular extravasation, especially in microvessels. To address these issues, nanoprobes based on red blood cell membrane-coated ultrasmall NaGdF nanoparticles that exhibit much higher longitudinal molar relaxivity () than the clinically used contrast agent gadolinium diethylenetriaminepentaacetic acid have been developed. Furthermore, the appropriate hydrodynamic diameter and stealth nature aid the nanoprobes to reside longer within the blood vessels without extravasation, thereby increasing the contrast between the blood vessels and surrounding tissues. Through probe-enhanced three-dimensional (3D) dynamic contrast-enhanced MR angiography, the main arteries and veins of the mouse were readily discernible, and even tiny vessels with sub-millimeter diameters could be clearly depicted. With this level of outstanding MR angiography performance, the embolization and recanalization processes of the carotid artery can be serially monitored with high imaging resolution using only a single injection. Additionally, the results of clearance studies and the toxicity tests further highlight the safety features of the nanoprobe. To summarize, the nanoprobes used in this study exhibit less extravascular leakage and a longer blood half-life, thus successfully overcoming the defects of the conventional low-molecular-weight Gd-based contrast agents and demonstrating their potential usefulness in enhanced MR angiography.
基于磁共振成像(MRI)的增强血管造影术已成为一种用于血管疾病临床评估的非侵入性、强大且高分辨率的成像技术。然而,临床使用的钆螯合造影剂的效果对于MRI对比增强并不理想,因为它们会因血管快速外渗导致血液半衰期短,尤其是在微血管中。为了解决这些问题,已经开发出了基于红细胞膜包裹的超小NaGdF纳米颗粒的纳米探针,其纵向摩尔弛豫率()比临床使用的造影剂钆二乙三胺五乙酸高得多。此外,合适的流体动力学直径和隐身特性有助于纳米探针在血管内停留更长时间而不外渗,从而增加血管与周围组织之间的对比度。通过探针增强的三维(3D)动态对比增强磁共振血管造影术,可以很容易地分辨出小鼠的主要动脉和静脉,甚至直径小于一毫米的微小血管也能清晰描绘。凭借这种出色的磁共振血管造影性能,仅通过一次注射就可以使用高成像分辨率连续监测颈动脉的栓塞和再通过程。此外,清除研究结果和毒性测试进一步突出了纳米探针的安全特性。总之,本研究中使用的纳米探针表现出较少的血管外渗漏和更长的血液半衰期,从而成功克服了传统低分子量钆基造影剂的缺陷,并证明了它们在增强磁共振血管造影中的潜在用途。